Benign prostatic hyperplasia (BPH) can have a profound affect on a patient's quality of life and sexual function and is considered by patients to be one of the most important aspects affected by the disease. Different treatments can produce a variable response in terms of the patient's quality of life, including sexual activity and satisfaction. Varying rates of erectile dysfunction (ED) and retrograde ejaculation following surgery for BPH have been reported. In general, the incidence of these side-effects is less after minimally invasive therapies, such as interstitial laser coagulation and transurethral microwave therapy, but the data available are limited. The lowest rates of sexual dysfunction are reported with medical therapies. The 5a-reductase inhibitor, finasteride, can result in ED in 5 -9% of patients and ejaculation disorders in 0.8 -2.0%. With the exception of tamsulosin, a 1 blockers are associated with a low rate of sexual dysfunction. No cases of ED have been reported with alfuzosin and abnormal ejaculation with terazosin or alfuzosin is negligible. Indeed, early research suggests a beneficial effect of a 1 blockers on sexual function. In addition to information on the efficacy of a particular therapy, patients should be informed of side effects, in particular those relating to sexual function, in order that they can make informed treatment decisions. Prostate Cancer and Prostatic Diseases (2001) 4, Suppl 1, S12-S16.
Introduction
Although not considered to be a life-threatening disease, benign prostatic hyperplasia (BPH) can seriously affect the patient's normal physical and social activities, and may have a profound effect on quality of life. 1, 2 From the urologist's point of view, this impact of treatment on sexuality, be it medical, surgical or instrumental, has often been poorly investigated and neglected.
From the patient's perspective, one of the major aspects of quality of life is sexuality following treatment for BPH. 3 A recent study evaluated which aspects of quality of life were most affected by prostatic symptoms and those which the patient considered most important. 3 A selfadministered questionnaire composed of 89 items was completed by 117 patients with an International Prostate Symptom Score (IPSS) > 7. The aspects reported to be most affected and the most important were sleep, anxiety and worry about the disease, mobility, leisure, daily activities, but above all sexual activities and satisfaction with sexual relationships.
Evaluation of sexual function
The most useful and comprehensive study of the epidemiology of erectile dysfunction (ED) at present is the Massachusetts Male Aging Study (MMAS), which was conducted between 1987 and 1989. 4 This cross-sectional, random sample survey of health status and related issues was conducted in men between the ages of 40 and 70 y. Analysis of data on 1209 men indicated that the mean probability of some degree of ED was 52.0%. Between the fifth and seventh decades, the probability of complete ED almost tripled from 5.1% to 15%.
Helgason et al showed that only 17% of men over 50 y reported that they could live without a sex life. 5 Another study evaluated the sexual function of an unselected population referred for hospital treatment for clinical BPH. 6 A total of 401 patients completed a questionnaire, which included three questions on sexuality: erection, ejaculation volume and pain/discomfort during ejaculation. Analysis of the results showed that the incidence of ED increased with age and related bother was much greater in younger males.
An important issue when discussing BPH and sexuality is to identify what specific aspects of sexual function are being considered; whether it is ED, ejaculation dysfunction, decreased libido or overall decreased sexual satisfaction. Assessment of sexual function is another important concern. Sexual dysfunction often occurs in the same subpopulation of men who are affected by symptomatic BPH. Consequently, the direct or indirect side effects of treatment for BPH on sexual function may be difficult to assess.
The lack of reproducible instruments to measure sexual function is another obstacle. Several different questionnaires are available including:
The Brief Sexual Function Inventory (SFI) 7 The International Index of Erectile Function (IIEF) 8 Urolife Scale 9 The Danish Prostatic Symptom Score (DAN-PSS) 10, 11 Of these, the SFI and the IIEF have been developed specifically to measure male sexual function.
Impact of treatment on sexual function
Different treatments can have the same impact on symptoms but may produce a variable response in terms of the patient's quality of life, which is influenced by the patient's preferences and values. For example, some patients with BPH may be more concerned about preserving or improving their actual sexuality than decreasing their potential risk of acute urinary retention by a moderate percentage. For some patients, retrograde ejaculation following transurethral resection of the prostate (TURP) may be an acceptable side effect of surgery if it has been properly discussed beforehand, while for others it represents a major issue. The actual impact that the various treatments have on sexual function is discussed below.
Surgery
Potential late sequelae of surgery for BPH include retrograde ejaculation and ED. Dependent on the series, 25 -99% of men lose ejaculation after surgery. 12 The impact of surgery on sexual function is difficult to assess and is also dependent on the patient's perception of his sexual ability before and after surgery, as well as on the presence of a sexual partner. This is also reflected by the variable rates of ED that have been reported to occur after TURP or open prostatectomy.
The American Urological Association (AUA) Cooperative Study reported a 13% incidence of ED following TURP. 13 A comparative study was conducted in which men were randomised to treatment with TURP or transurethral vaporisation of the prostate (TUVP). Postoperative ED was reported in 17 and 11% and retrograde ejaculation in 72 and 89% of patients treated with TURP and TUVP, respectively. 14 A second comparative trial resulted in retrograde ejaculation in 68 and 35% of patients undergoing TURP and transurethral incision of the prostate (TUIP), respectively. 15 Follow-up after TURP with regard to sexual function was studied by Kinn and associates. 16 A total of 127 men completed a questionnaire on personal evaluation of sexual function, including erection, ejaculation, libido and satisfaction. Of the responders, 54% stated that there was deterioration in all of these factors and importantly, 50% attributed this to the surgery they had undergone, ie TURP.
Minimally invasive therapies
A number of minimally invasive treatments have been developed for symptomatic BPH, including transurethral needle ablation (TUNA), transurethral microwave thermotherapy (TUMT), interstitial laser coagulation (ILC). The effect on sexual function of these therapies has been evaluated; however, a variety of assessment methods were used.
With regard to ILC, retrograde ejaculation was reported in 6% of patients in a study by Arai et al 17 and 0 -11.9% in others; 18 no cases of ED have been described with ILC. 18, 19 The incidence of sexual dysfunction is negligible after TUNA; several studies reported no ED or retrograde ejaculation. 20 -22 Only one study, a prospective multicentre trial in the US, found less than 1 and 2% of retrograde ejaculation and ED, respectively. 23 Limited data are available on TUMT. Francisca et al studied 50 patients treated with TUMT or by sham and found that 20% of patients treated with either modality had a worsened sexual function at 26 weeks post-treatment. 24 The overall incidence of retrograde ejaculation was 11% and for lack of orgasms, 14%. Interestingly, at baseline and at 12 and 26 weeks post-treatment, there was no statistically significant difference between TUMT and sham treatment with regard to quality of life related to sexual function.
Medical therapy
Finasteride. Finasteride is a selective 5a-reductase inhibitor that reduces the conversion of testosterone to dihydrotestosterone. It has been shown to improve symptoms in patients with BPH over a period of 3 -6 months, and the efficacy of the drug appears to be related to prostate size over 40 ml. 25 The effect of finasteride on sexual function is summarised in Table 1 . 26 -28 Increased risk of various side effects related to sexual function were demonstrated with finasteride.
Phytotherapy. There are very few placebo controlled studies on phytotherapy for BPH evaluating the impact on sexual function. A 6 month study compared the effects of Serenoa repens, a plant extract, with finasteride in 1098 men with moderate BPH. 29 The effect on sexual function was assessed in a sexual questionnaire and indicated that Serenoa repens resulted in fewer complaints of decreased libido and ED, although the percentages reported were low. a 1 blockers. A variety of a 1 blockers are available and their use generally results in a 6 -31% improvement in symptom score within the first 2 -3 weeks. 30, 31 Maximum urinary flow rate can also be increased by up to 3.9 ml/s. 30 In terms of sexual function, the effect of the different a 1 blockers on ejaculation is shown in Table 2 . 26,31 -37 The European Tamsulosin Group reported that at 3 y follow-up, 2.9% of patients had ED and 4.3% ejaculation disorders. 35, 38 In contrast to the other a 1 blockers, doxazosin has been poorly studied with regard to sexual satisfaction.
Clearly, a 1 blockers do not have the adverse effect on sexual function that certain other therapies exhibit. The ALFIN Study in addition to comparing the efficacy of alfuzosin and finasteride and their combination in BPH, also examined the effect of these therapies on erection and ejaculation using the DAN-PSS questionnaire. 39, 40 A total of 1051 patients aged 50 -75 y were enrolled in the study. The effects of therapy on ED and ejaculatory function are shown in Figures 1 and 2 . 39, 40 Results showed that alfuzosin had very little effect on the ability to achieve an erection, whereas erectile function decreased with finasteride therapy and with the combination of the two drugs, presumably due to the contribution of finasteride. With regard to ejaculation, again, only finasteride and the combination had a detrimental effect.
It has been suggested that a 1 blockers may improve sexual function in patients with BPH. A study of 2829 patients with BPH treated with alfuzosin 2.5 mg t.i.d. or 5 mg b.i.d. for 1 y was conducted in the primary care setting. 41 Sex drive, erections and overall sexual satisfaction were assessed using the Urolife 2 BPHQoL9. Data were analysed according to patient age and symptom severity and baseline patient characteristics are shown in Table 3 . Following treatment with alfuzosin, particularly in the younger age group, there was an appreciable improvement in overall sex life in patients with moderate and severe symptoms (Figures 3 and 4 ). 41 Figure 1 Effect of therapy on the ability to achieve an erection in the ALFIN Study. 37, 38 Figure 2 Effect of therapy on ejaculatory function in the ALFIN Study. 37, 38 Treatment of BPH and sexuality C Schulman
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Lower urinary tract symptoms of BPH, voiding problems and ED are related to sympathetic overactivity, which comes with age. It is possible that the use of a 1 blockers may relieve not only symptoms of BPH and hypertension, but also decrease the sympathetic tone at the penile level. 38 Evidence exists for the potential benefits of other a 1 blockers on sexual function. In one study, patients with BPH were treated with doxazosin for up to 8 weeks and assessed at weeks 4 and 8 using a sexual function questionnaire. 42 Results showed that doxazosin significantly improved overall sexual function compared with baseline values and, in particular, the ability to gain and keep an erection. A 10% improvement in overall sexual function was noted at week 4 (P ¼ 0.002) and a 15% improvement at week 8 (P < 0.001).
Perhaps the strongest evidence for the benefits of a 1 blockers in improving sexual function comes from their intracavernous use in patients with ED. Colson conducted a retrospective study on 1001 patients with total or partial ED treated with three different vasoactive preparations: moxisylyte (n ¼ 476), PGE1 (n ¼ 195) or papaverine (n ¼ 170); 160 patients were given a mixture of monotherapy and combined therapy. 43 Results indicate that moxisylyte was superior to the other intracavernous treatments with regard to: return of satisfactory sexual activity after discontinuation of therapy; reappearance and improvement of spontaneous erections; and return of the penis to its usual size. Intracavernosal injection of phenoxybenzamine, another a 1 blocker, has also been shown to produce full erections lasting for over 30 min in men with ED. 44 
Conclusion
In making treatment decisions for BPH it is necessary to consider the balance between efficacy, side effects and the potentially beneficial effect of treating patients at an early stage, where the impact on voiding and sexual function may be greater. Quality of life for patients is clearly of great importance to them and the impact of treatment on sexual function should be considered more carefully. By improving patients' symptoms, a 1 blockers bring about a general improvement in the patient's wellbeing and a likely improvement in his sex drive. It is also essential to provide the patient with information on the consequences of therapy for the disease, in particular the effects on quality of life and sexual function, in order that their treatment preferences and priorities can be taken into account. 
Figure 3
Improvement in sexual score in patients with moderate symptoms of BPH after 1 y of treatment with alfuzosin. 39, 40 Figure 4 Improvement in sexual score in patients with severe symptoms after 1 y of treatment with alfuzosin. 39, 40 Treatment of BPH and sexuality C Schulman S15 Prostate Cancer and Prostatic Diseases
